Patent details
91122
Product Name:
Efalizumab et ses dérivés pharmaceutiquement acceptables (RAPTIVA®)
Basic Information
- Publication number:
- 91122
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
-
EP979128410
- Legal Status:
- Expired
- Application number:
- 91122
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/04/291/001
- Marketing Authorization Type:
-
- Marketing Authorization Date:
- 20/09/2004
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
-
Dates
- Filing date:
- 10/11/2004
- First Marketing Authorization date:
- 20/09/2004
- Grant date:
- 10/01/2005
- Activation date:
- 20/10/2017
- Publication date:
- 10/01/2005
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 20/09/2019
- SPC Extension Expiration:
- 20/09/2019
- Rejection date:
- Withdrawal date:
Owner
- From:
- 10/11/2004
-
-
- Name:
- Genentech Inc.
- Address:
- 1 DNA Way, South San Francisco, CA 94080-4990, United States (US)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 10/11/2004
- Address:
- PO Box 48, 8001, STRASSEN, Luxembourg (LU)
- To:
Inventor
1
- Name:
- PRESTA Leonard, G.
- Address:
- United States (US)
2
- Name:
- JARDIEU Paula, M.
- Address:
- United States (US)
Publication
Bulletin
- Bulletin Heading:
- SPC3
- Bulletin edition number:
- 2017/07
- Publication date:
- 11/12/2017
- Description:
- Section E : Supplementary Protection certificates entered into force – IA publication
Annual Fees
- Annual Fee Due Date:
-
- Annual Fee Number:
-
- Expected Payer:
-
- Last Annual Fee Payment Date:
- 04/10/2018
- Last Annual Fee Paid Number:
- 22
- Last Annual Fee Paid Amount:
- 420 Euro
- Payer:
- MDC (HENKEL PATENT)
Filing date |
Document type |
Number of pages |